サマリー

画像誘導放射線治療の世界市場は、2023年の19億米ドルから2028年には24億米ドルに達し、予測期間中のCAGRは5.2％で成長すると予測されている。画像誘導放射線治療（IGRT）市場の急成長が予測される背景には、魅力的な利点が数多くある。特に、IGRTの腫瘍ターゲティングの精度の高さは、健康な組織への付随的なダメージを軽減する能力と相まって、極めて重要な推進力となっている。さらに、世界的ながん罹患率の上昇により、先進的な治療法に対する需要が高まっており、IGRTはその最前線のソリューションとして位置づけられている。このような要因が重なることで、市場は堅調な拡大局面を迎えることになり、IGRT採用の展望が今後数年間で形成されることになる。

"リニアック（線形加速器）セグメントが2022-2028年に最大市場シェアを記録"
画像誘導放射線治療市場は、製品に基づき、4Dゲーティング/4D RT、リニアック（リニアック）、PET/MRI誘導放射線治療、CTスキャン、ポータルイメージングに区分される。リニアック（線形加速器）分野は、2022-2028年の予測期間で最大の市場シェアを記録する。リニアック技術の領域は絶え間ない進化を遂げており、画像モダリティ、線量送達方法論、治療検証アプローチを包含する進歩的な技術革新が特徴である。この進化の軌跡は、画像誘導放射線治療（IGRT）の永続的な進歩に大きく寄与しており、それによって市場の存在感と卓越性を高める上で極めて重要な役割を果たしている。

「2023～2028年の予測期間で最も高いCAGRを記録するのは前立腺がんのアプリケーション分野である。
画像誘導放射線治療市場は、用途別に前立腺がん、肺がん、頭頸部がん、乳がん、消化器がん、婦人科がん、その他の用途に区分される。前立腺がんの世界的な増加により、先進的で効果的な治療方法に対するニーズが高まっている。このような枠組みの中で、画像誘導放射線治療（IGRT）は極めて重要な位置を占めており、精度の高い緻密な腫瘍ターゲティングを提供し、治療成績を向上させている。このような治療の高度化に対する要求の高まりは、IGRTの固有の特性とシームレスに融合し、前立腺がん放射線療法領域における市場拡大を推進する中心的な地位を立証している。


「予測期間中、画像誘導放射線治療市場で最も高いCAGRを占めたのは定位治療であった。
手技に基づき、画像誘導放射線治療市場は3Dコンフォーマル治療、IMRT、定位治療、粒子線治療、陽子線治療に区分される。予測期間中、画像誘導放射線治療市場において最も大きな年間平均成長率（CAGR）を示したのは定位治療であった。
定位放射線治療には、治療期間の短縮や精度の向上など、放射線治療を受ける患者の快適性を高める特長がある。このような全人的な治療体験の向上は、画像誘導放射線治療（IGRT）を支える患者中心の哲学とシームレスに一致する。このような特性の融合は、患者の治療成績を向上させるだけでなく、IGRTの市場環境における魅力を増幅させ、その結果、採用率の向上と市場での存在感を高めることになる。

「2022-2028年に画像誘導放射線治療市場で最大の市場シェアを占めるのは病院セグメント
画像誘導放射線治療市場の主要エンドユーザーは病院である。予測期間中、病院のエンドユーザー部門が画像誘導放射線治療市場で大きな市場シェアを占めると推定されている。病院は、1つの施設内で総合的な医療サービスを提供できることが特徴であり、画像誘導放射線治療（IGRT）を受ける患者に独特の利便性をもたらしている。この利便性は、多様な医療ニーズをひとつ屋根の下に集約することにより、患者が別々の場所で複数の予約を取る必要性を軽減することに由来する。このような戦略的なサービスの統合は、患者の治療を合理化するだけでなく、IGRTの治療オプションとしての魅力を高める。その結果、利便性と包括的ケアのシームレスな連携が、病院内での画像誘導放射線治療市場の発展と隆盛に大きく寄与している。
技術の進歩：病院は、画像誘導放射線治療（IGRT）の統合を成功させるために不可欠な最先端のインフラや技術的能力を維持することが多く、必要なリソースをすぐに利用できる。この極めて重要な特性は、画像誘導放射線治療市場の発展と強化に明確に寄与している。


「予測期間中、アジア太平洋地域が市場の著しい成長率を記録する」。
予測期間2023-2028年において、APAC地域は予測期間中に市場で著しい成長率を記録すると予想されている。アジア太平洋地域は、インド、中国、日本、オーストラリア、韓国、RoAPACで構成される。アジア太平洋（APAC）地域は、画像誘導放射線治療の市場成長率が大幅に上昇している。この成長にはいくつかの要因がある：
APAC諸国では人口動態が成熟しつつあり、治療に関連する副作用を最小限に抑えた効率的ながん治療法が求められている。画像誘導放射線治療（IGRT）の精密さ主導の特性との共鳴は、市場展望を拡大する上で極めて重要な役割を果たしている。
APACの病院では、多言語による患者ケアを提供しており、画像誘導放射線治療（IGRT）のような先進治療へのアクセスも容易であることから、特に多様な患者の間で、この地域に独自の魅力を与えている。このような言語による包括性と最先端の医療介入との融合は、この地域が好まれている医療目的地としての望ましさを著しく高め、その結果、医療市場における競争力を強化し、IGRTの隆盛を後押ししている。

本レポートの主な参加企業の内訳は以下の通りである：
- 企業タイプ別ティア1-40％、ティア2-30％、ティア3-30
- 役職別Cレベル-27％、ディレクターレベル-18％、その他-55
- 地域別北米-50%、欧州-20%、アジア太平洋地域-15%、中南米-10%、中東・アフリカ-5

同市場における主なプレーヤーは、シーメンス・ヘルティニアスAG（ドイツ）、エレクタ（スウェーデン）、アキュレイ・インコーポレイテッド（米国）、GEヘルスケア・カンパニー（米国）、日立製作所（日本）などである。

調査範囲

- この調査レポートは、画像誘導放射線治療市場を製品、手技、用途、エンドユーザー、地域別に調査しています。
- 市場成長に影響を与える要因（促進要因、阻害要因、機会、課題など）を分析しています。
- 関係者向けに市場の機会と課題を評価し、市場リーダー向けに競争環境の詳細を提供しています。
- 当レポートでは、微小市場の成長動向、展望、世界の画像誘導放射線治療市場への貢献に関して調査しています。
- 主要5地域に関して市場セグメントの収益を予測しています。

レポート購入の主な利点

本レポートは、包括的なデータの徹底的な分析を通じて、画像誘導放射線治療市場における投資評価の実行可能性について、市場リーダー/新規参入企業/中小企業の助けとなり、それによって強固なリスク評価が容易になり、十分な情報に基づいた投資決定が可能になります。当レポートでは、アプリケーション、エンドユーザー、地域別に細分化された詳細な市場分析により、的確なセグメントターゲティングを可能にするテーラーメイドのインサイトを提供します。また、極めて重要なトレンド、成長触媒、課題、展望を網羅的に評価し、鋭い洞察力で戦略的意思決定を後押しします。
本レポートは、以下のポイントに関する洞察を提供しています：
- 画像誘導放射線療法市場の成長に影響を与える主要な促進要因（がん患者の増加、がん管理に対する政府の取り組みの増加、放射線療法による非侵襲的治療の進歩）、阻害要因（熟練した放射線科医/腫瘍医の不足、画像誘導放射線療法治療の高コスト、治療のための画像技術の複雑さ）、機会（新興国における主要企業の拡大、発展途上国における医療費の増加）、課題（代替技術の利用可能性）の分析
- 製品開発/イノベーション：画像誘導放射線治療市場における今後の技術、研究開発活動、新製品・サービス開始に関する詳細な洞察。
- 市場開発：有利な市場に関する包括的な情報 - 当レポートでは、様々な地域における画像誘導放射線治療市場を分析しています。
- 市場の多様化：画像誘導放射線治療市場における新製品、未開拓地域、最近の開発、投資に関する詳細な情報
- 競合評価：Siemens Healthineers AG（ドイツ）、Elekta（スウェーデン）、Accuray Incorporated（米国）などの主要企業の市場シェア、成長戦略、サービス内容を詳細に評価。

ページTOPに戻る

目次

1 INTRODUCTION 25
1.1 STUDY OBJECTIVES 25
1.2 MARKET DEFINITION 25
1.2.1 INCLUSIONS AND EXCLUSIONS 25
1.3 MARKET SCOPE 26
1.3.1 MARKETS COVERED 26
1.3.2 REGIONS COVERED 26
1.3.3 YEARS CONSIDERED 27
1.3.4 CURRENCY CONSIDERED 27
1.4 RESEARCH LIMITATIONS 27
1.5 MARKET STAKEHOLDERS 28
1.6 SUMMARY OF CHANGES 28
1.6.1 RECESSION IMPACT 29
2 RESEARCH METHODOLOGY 30
2.1 RESEARCH DATA 30
FIGURE 1 RESEARCH DESIGN 31
2.1.1 SECONDARY DATA 31
2.1.1.1 Key data from secondary sources 33
2.1.2 PRIMARY RESEARCH 33
2.1.2.1 Primary sources 34
2.1.2.2 Key industry insights 35
2.1.2.3 Breakdown of primaries 35
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY AND DEMAND-SIDE PARTICIPANTS 35
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 36
2.2 MARKET SIZE ESTIMATION 36
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 37
2.2.1 BOTTOM-UP APPROACH 37
2.2.1.1 Approach 1: Company revenue estimation approach 38
FIGURE 5 IMAGE-GUIDED RADIATION THERAPY MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ESTIMATION) 38
2.2.1.2 Approach 2: Customer-based market estimation 39
FIGURE 6 IMAGE-GUIDED RADIATION THERAPY MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 39
2.2.1.3 Approach 3: Top-down approach 39
2.2.1.4 Approach 4: Primary interviews 40
FIGURE 7 TOP-DOWN APPROACH 40
2.3 DATA TRIANGULATION AND MARKET BREAKDOWN 42
FIGURE 8 DATA TRIANGULATION METHODOLOGY 42
2.4 ASSUMPTIONS AND RISK ASSESSMENT 43
TABLE 1 IMAGE-GUIDED RADIATION THERAPY MARKET: ASSUMPTIONS 43
TABLE 2 IMAGE-GUIDED RADIATION THERAPY MARKET: LIMITATIONS 43
2.5 RECESSION IMPACT ANALYSIS 44
3 EXECUTIVE SUMMARY 45
FIGURE 9 IMAGE-GUIDED RADIATION THERAPY MARKET, BY TECHNIQUE, 2023 VS. 2028 (USD MILLION) 45
FIGURE 10 IMAGE-GUIDED RADIATION THERAPY MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 46
FIGURE 11 IMAGE-GUIDED RADIATION THERAPY MARKET, BY PROCEDURE, 2023 VS. 2028 (USD MILLION) 47
FIGURE 12 IMAGE-GUIDED RADIATION THERAPY MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 48
FIGURE 13 IMAGE-GUIDED RADIATION THERAPY MARKET: GEOGRAPHICAL SNAPSHOT 49
4 PREMIUM INSIGHTS 50
4.1 IMAGE-GUIDED RADIATION THERAPY MARKET OVERVIEW 50
FIGURE 14 INCREASING CANCER PATIENT POPULATION AND GROWING NONINVASIVE CANCER TREATMENT TO DRIVE MARKET 50
4.2 REGIONAL MIX: IMAGE-GUIDED RADIATION THERAPY MARKET (2021–2028) 51
FIGURE 15 NORTH AMERICA TO DOMINATE MARKET THROUGHOUT FORECAST PERIOD 51
4.3 NORTH AMERICA: IMAGE-GUIDED RADIATION THERAPY MARKET, BY COUNTRY AND END USER, 2022 (USD MILLION) 52
FIGURE 16 HOSPITALS DOMINATED IMAGE-GUIDED RADIATION THERAPY MARKET IN 2022 52
4.4 IMAGE-GUIDED RADIATION THERAPY MARKET, BY COUNTRY 52
FIGURE 17 MEXICO TO GROW AT HIGHEST RATE IN GLOBAL MARKET 52
5 MARKET OVERVIEW 53
5.1 INTRODUCTION 53
5.2 MARKET DYNAMICS 53
FIGURE 18 IMAGE-GUIDED RADIATION THERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 53
5.2.1 DRIVERS 54
5.2.1.1 Rising adoption of radiotherapy for noninvasive cancer treatment 54
5.2.1.2 Rising cancer patient population 54
FIGURE 19 OVERVIEW OF CANCER PATIENT POPULATION: MALE VS. FEMALE 55
TABLE 3 RISE IN CANCER CASES, 2020 VS. 2025 VS. 2030 55
5.2.1.3 Initiatives and support for cancer management 56
5.2.2 RESTRAINTS 56
5.2.2.1 Complexity of imaging technology 56
5.2.2.2 Affordability and accessibility of treatment 57
5.2.3 OPPORTUNITIES 57
5.2.3.1 Expansion of key players in emerging economies 57
5.2.3.2 Rising healthcare expenditure across emerging economies 58
FIGURE 20 GOVERNMENT HEALTH EXPENDITURE AS % OF GENERAL GOVERNMENT EXPENDITURE (GGE) 58
5.2.4 CHALLENGES 59
5.2.4.1 Availability of alternatives to IGRT 59
5.2.4.2 Dearth of skilled personnel 59
5.3 PORTER’S FIVE FORCES ANALYSIS 60
TABLE 4 IMAGE-GUIDED RADIATION THERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS 60
5.3.1 THREAT OF NEW ENTRANTS 60
5.3.2 THREAT OF SUBSTITUTES 60
5.3.3 BARGAINING POWER OF SUPPLIERS 60
5.3.4 BARGAINING POWER OF BUYERS 60
5.3.5 INTENSITY OF COMPETITIVE RIVALRY 61
5.4 ECOSYSTEM MAPPING 61
FIGURE 21 IMAGE-GUIDED RADIATION THERAPY MARKET: ECOSYSTEM MAP 61
5.5 VALUE CHAIN ANALYSIS 62
5.5.1 RESEARCH & DEVELOPMENT 62
5.5.2 PROCUREMENT AND PRODUCT DEVELOPMENT 62
5.5.3 MARKETING, SALES & DISTRIBUTION, AND POST-SALES SERVICES 62
FIGURE 22 IMAGE-GUIDED RADIATION THERAPY MARKET: VALUE CHAIN ANALYSIS 62
5.6 SUPPLY CHAIN ANALYSIS 63
5.6.1 PROMINENT COMPANIES 63
5.6.2 SMALL & MEDIUM-SIZED COMPANIES 63
5.6.3 END USERS 63
FIGURE 23 IMAGE-GUIDED RADIATION THERAPY MARKET: SUPPLY CHAIN ANALYSIS 63
5.7 REGULATORY ANALYSIS 64
5.7.1 US 64
TABLE 5 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 65
5.7.2 EUROPE 65
5.7.3 JAPAN 65
TABLE 6 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA 66
5.8 REIMBURSEMENT SCENARIO 66
TABLE 7 CPT CODES FOR MAJOR AUTOMATED RADIATION THERAPY TREATMENT MODALITIES 66
TABLE 8 HEALTHCARE COMMON PROCEDURE CODING SYSTEM (HCPCS) CODES FOR IGRT 67
TABLE 9 REIMBURSEMENT FOR IMAGE-GUIDED RADIATION THERAPY PROCEDURES PER COURSE, 2021 VS. 2022 67
TABLE 10 FREESTANDING PER COURSE NATIONAL AVERAGE MEDICARE REIMBURSEMENT, 2021 VS. 2022 68
5.9 PRICING ANALYSIS 68
TABLE 11 PRICING ANALYSIS OF AUTOMATED RADIATION SYSTEMS (USD) 68
5.10 PATENT ANALYSIS 69
TABLE 12 IMPORT DATA FOR IMAGE-GUIDED RADIATION THERAPY (HS CODE 9022), BY COUNTRY, 2018–2022 (USD THOUSAND) 69
TABLE 13 EXPORT DATA FOR IMAGE-GUIDED RADIATION THERAPY (HS CODE 9018), BY COUNTRY, 2018–2022 (USD THOUSAND) 70
5.11 CASE STUDY 70
TABLE 14 CASE STUDY: ENABLING MR-GUIDED SBRT TREATMENTS FOR PROSTATE CANCER 70
5.12 KEY CONFERENCES AND EVENTS, 2023–2024 71
TABLE 15 IMAGE-GUIDED RADIATION THERAPY MARKET: DETAILED LIST OF KEY CONFERENCES AND EVENTS IN 2023–2024 71
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 72
FIGURE 24 EMERGING TRENDS AND OPPORTUNITIES AFFECTING FUTURE REVENUE MIX 72
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA 72
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 72
FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR IMAGE-GUIDED RADIATION THERAPY MARKET 72
TABLE 16 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR KEY PRODUCT SEGMENTS (%) 73
5.15 IMAGE-GUIDED RADIATION THERAPY MARKET: RECESSION IMPACT 73
6 IMAGE-GUIDED RADIATION THERAPY MARKET, BY TECHNIQUE 74
6.1 INTRODUCTION 75
TABLE 17 IMAGE-GUIDED RADIATION THERAPY MARKET, BY TECHNIQUE, 2020–2028 (USD MILLION) 75
6.2 LINACS 75
6.2.1 LINACS TO HOLD LARGEST MARKET SHARE TILL 2028 75
TABLE 18 LINACS MARKET, BY REGION, 2020–2028 (USD MILLION) 76
TABLE 19 LINACS MARKET, BY PROCEDURE, 2020–2028 (USD MILLION) 76
TABLE 20 LINACS MARKET, BY APPLICATION, 2020–2028(USD MILLION) 77
TABLE 21 LINACS MARKET, BY END USER, 2020–2028 (USD MILLION) 77
6.3 CT SCANNING 77
6.3.1 GROWING NUMBER OF IMAGE-GUIDED AND MINIMALLY INVASIVE MEDICAL PROCEDURES TO BOOST MARKET 77
TABLE 22 CT SCANNING MARKET, BY REGION, 2020–2028 (USD MILLION) 78
TABLE 23 CT SCANNING MARKET, BY PROCEDURE, 2020–2028 (USD MILLION) 78
TABLE 24 CT SCANNING MARKET, BY APPLICATION, 2020–2028 (USD MILLION) 79
TABLE 25 CT SCANNING MARKET, BY END USER, 2020–2028 (USD MILLION) 79
6.4 PORTAL IMAGING 79
6.4.1 TRANSITION FROM MANUAL TO ROBOTIC TREATMENT TO SUPPORT MARKET GROWTH 79
TABLE 26 PORTAL IMAGING MARKET, BY REGION, 2020–2028 (USD MILLION) 80
TABLE 27 PORTAL IMAGING MARKET, BY PROCEDURE, 2020–2028 (USD MILLION) 80
TABLE 28 PORTAL IMAGING MARKET, BY APPLICATION, 2020–2028 (USD MILLION) 81
TABLE 29 PORTAL IMAGING MARKET, BY END USER, 2020–2028 (USD MILLION) 81
6.5 4D GATING/4D RADIATION THERAPY 82
6.5.1 RISING NUMBER OF CANCER TREATMENTS TO DRIVE MARKET 82
TABLE 30 4D GATING/4D RADIATION THERAPY MARKET, BY REGION, 2020–2028 (USD MILLION) 82
TABLE 31 4D GATING/4D RADIATION THERAPY MARKET, BY PROCEDURE, 2020–2028 (USD MILLION) 82
TABLE 32 4D GATING/4D RADIATION THERAPY MARKET, BY APPLICATION, 2020–2028 (USD MILLION) 83
TABLE 33 4D GATING/4D RADIATION THERAPY MARKET, BY END USER, 2020–2028 (USD MILLION) 83
6.6 PET/MRI-GUIDED RADIATION THERAPY 83
6.6.1 LARGE PATIENT POPULATION FOR CANCER TO DRIVE MARKET 83
TABLE 34 PET/MRI-GUIDED RADIATION THERAPY MARKET, BY REGION, 2020–2028 (USD MILLION) 84
TABLE 35 PET/MRI-GUIDED RADIATION THERAPY MARKET, BY PROCEDURE, 2020–2028 (USD MILLION) 84
TABLE 36 PET/MRI-GUIDED RADIATION THERAPY MARKET, BY APPLICATION, 2020–2028 (USD MILLION) 85
TABLE 37 PET/MRI-GUIDED RADIATION THERAPY MARKET, BY END USER, 2020–2028 (USD MILLION) 85
7 IMAGE-GUIDED RADIATION THERAPY MARKET, BY PROCEDURE 86
7.1 INTRODUCTION 87
TABLE 38 IMAGE-GUIDED RADIATION THERAPY MARKET, BY PROCEDURE, 2020–2028 (USD MILLION) 87
7.2 IMRT 87
7.2.1 IMRT TO HOLD LARGEST MARKET SHARE OVER FORECAST PERIOD 87
TABLE 39 IMRT MARKET, BY REGION, 2020–2028 (USD MILLION) 88
7.3 3D CONFORMAL RADIATION THERAPY 88
7.3.1 ADVANTAGES AND INCREASED ADOPTION OF RADIATION THERAPY TO BOOST ADOPTION 88
TABLE 40 3D CONFORMAL RADIATION THERAPY MARKET, BY REGION, 2020–2028 (USD MILLION) 89
7.4 STEREOTACTIC THERAPY 89
7.4.1 HIGH PRECISION AND EASE OF USE FOR SURGEONS TO DRIVE ADOPTION 89
TABLE 41 STEREOTACTIC THERAPY MARKET, BY REGION, 2020–2028 (USD MILLION) 90
7.5 PARTICLE THERAPY 90
7.5.1 GOVERNMENT SUPPORT TO BOOST NUMBER OF PARTICLE THERAPY CENTERS 90
TABLE 42 PARTICLE THERAPY MARKET, BY REGION, 2020–2028 (USD MILLION) 90
7.6 PROTON BEAM THERAPY 91
7.6.1 RISING ESTABLISHMENT OF PROTON THERAPY CANCER CENTERS TO DRIVE MARKET 91
TABLE 43 PROTON BEAM THERAPY MARKET, BY REGION, 2020–2028 (USD MILLION) 91
8 IMAGE-GUIDED RADIATION THERAPY MARKET, BY APPLICATION 92
8.1 INTRODUCTION 93
TABLE 44 IMAGE-GUIDED RADIATION THERAPY MARKET, BY APPLICATION, 2020–2028 (USD MILLION) 93
8.2 BREAST CANCER 93
8.2.1 BREAST CANCER TO HOLD LARGEST SHARE OF APPLICATIONS MARKET 93
TABLE 45 IMAGE-GUIDED RADIATION THERAPY MARKET FOR BREAST CANCER, BY REGION, 2020–2028 (USD MILLION) 94
8.3 LUNG CANCER 94
8.3.1 RISING NUMBER OF CLINICAL TRIALS TO SUPPORT GROWTH 94
TABLE 46 IMAGE-GUIDED RADIATION THERAPY MARKET FOR LUNG CANCER, BY REGION, 2020–2028 (USD MILLION) 95
8.4 PROSTATE CANCER 95
8.4.1 PREFERENCE FOR NONINVASIVE TREATMENT TO BOOST GROWTH 95
TABLE 47 IMAGE-GUIDED RADIATION THERAPY MARKET FOR PROSTATE CANCER, BY REGION, 2020–2028 (USD MILLION) 95
8.5 HEAD & NECK CANCER 96
8.5.1 RISING AWARENESS OF BENEFITS OF NONINVASIVE TREATMENTS TO SUPPORT GROWTH 96
TABLE 48 IMAGE-GUIDED RADIATION THERAPY MARKET FOR HEAD & NECK CANCER, BY REGION, 2020–2028 (USD MILLION) 96
8.6 GYNECOLOGICAL CANCER APPLICATIONS 97
8.6.1 GROWING AWARENESS AND NEED FOR EARLY, EFFECTIVE TREATMENT TO SUPPORT ADOPTION 97
TABLE 49 IMAGE-GUIDED RADIATION THERAPY MARKET FOR GYNECOLOGICAL CANCER, BY REGION, 2020–2028(USD MILLION) 97
8.7 GASTROINTESTINAL CANCER 97
8.7.1 RISING GI CANCER INCIDENCE TO BOOST MARKET GROWTH 97
TABLE 50 IMAGE-GUIDED RADIATION THERAPY MARKET FOR GASTROINTESTINAL CANCER, BY REGION, 2020–2028 (USD MILLION) 98
8.8 OTHER APPLICATIONS 98
TABLE 51 IMAGE-GUIDED RADIATION THERAPY MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2028 (USD MILLION) 99
9 IMAGE-GUIDED RADIATION THERAPY MARKET, BY END USER 100
9.1 INTRODUCTION 101
TABLE 52 IMAGE-GUIDED RADIATION THERAPY MARKET, BY END USER, 2020–2028 (USD MILLION) 101
9.2 HOSPITALS 101
9.2.1 LARGE NUMBER OF SURGICAL AND DIAGNOSTIC PROCEDURES TO PROPEL MARKET 101
TABLE 53 IMAGE-GUIDED RADIATION THERAPY MARKET FOR HOSPITALS, BY REGION, 2020–2028 (USD MILLION) 102
9.3 INDEPENDENT RADIOTHERAPY CENTERS 102
9.3.1 LIMITED SURGICAL CAPABILITIES OF AVAILABLE PRODUCTS TO RESTRAIN ADOPTION 102
TABLE 54 IMAGE-GUIDED RADIATION THERAPY MARKET FOR INDEPENDENT RADIOTHERAPY CENTERS, BY REGION, 2020–2028 (USD MILLION) 103
10 IMAGE-GUIDED RADIATION THERAPY MARKET, BY REGION 104
10.1 INTRODUCTION 105
TABLE 55 IMAGE-GUIDED RADIATION THERAPY MARKET, BY REGION, 2020–2028 (USD MILLION) 105
10.2 NORTH AMERICA 105
10.2.1 NORTH AMERICA: RECESSION IMPACT 105
FIGURE 26 NORTH AMERICA: MARKET SNAPSHOT 106
TABLE 56 NORTH AMERICA: IMAGE-GUIDED RADIATION THERAPY MARKET, BY COUNTRY, 2020–2028 (USD MILLION) 107
TABLE 57 NORTH AMERICA: IMAGE-GUIDED RADIATION THERAPY MARKET, BY TECHNIQUE, 2020–2028 (USD MILLION) 107
TABLE 58 NORTH AMERICA: IMAGE-GUIDED RADIATION THERAPY MARKET, BY PROCEDURE, 2020–2028 (USD MILLION) 108
TABLE 59 NORTH AMERICA: IMAGE-GUIDED RADIATION THERAPY MARKET, BY APPLICATION, 2020–2028 (USD MILLION) 108
TABLE 60 NORTH AMERICA: IMAGE-GUIDED RADIATION THERAPY MARKET, BY END USER, 2020–2028 (USD MILLION) 109
10.2.2 US 109
10.2.2.1 US to dominate North American market 109
TABLE 61 US: IMAGE-GUIDED RADIATION THERAPY MARKET, BY TECHNIQUE, 2020–2028 (USD MILLION) 109
10.2.3 CANADA 110
10.2.3.1 Rising cancer prevalence and growing awareness to drive market 110
TABLE 62 CANADA: IMAGE-GUIDED RADIATION THERAPY MARKET, BY TECHNIQUE, 2020–2028 (USD MILLION) 110
10.3 EUROPE 111
10.3.1 EUROPE: RECESSION IMPACT 111
TABLE 63 EUROPE: IMAGE-GUIDED RADIATION THERAPY MARKET, BY COUNTRY, 2020–2028 (USD MILLION) 111
TABLE 64 EUROPE: IMAGE-GUIDED RADIATION THERAPY MARKET, BY TECHNIQUE, 2020–2028 (USD MILLION) 112
TABLE 65 EUROPE: IMAGE-GUIDED RADIATION THERAPY MARKET, BY PROCEDURE, 2020–2028 (USD MILLION) 112
TABLE 66 EUROPE: IMAGE-GUIDED RADIATION THERAPY MARKET, BY APPLICATION, 2020–2028 (USD MILLION) 113
TABLE 67 EUROPE: IMAGE-GUIDED RADIATION THERAPY MARKET, BY END USER, 2020–2028 (USD MILLION) 113
10.3.2 GERMANY 114
10.3.2.1 Germany to dominate market in Europe 114
TABLE 68 GERMANY: IMAGE-GUIDED RADIATION THERAPY MARKET, BY TECHNIQUE, 2020–2028 (USD MILLION) 114
10.3.3 UK 115
10.3.3.1 High burden of cancer and large volume of radiation therapy procedures to ensure demand 115
TABLE 69 UK: IMAGE-GUIDED RADIATION THERAPY MARKET, BY TECHNIQUE, 2020–2028 (USD MILLION) 115
10.3.4 FRANCE 115
10.3.4.1 Growth of French healthcare sector to support market growth 115
TABLE 70 FRANCE: IMAGE-GUIDED RADIATION THERAPY MARKET, BY TECHNIQUE, 2020–2028 (USD MILLION) 116
10.3.5 ITALY 116
10.3.5.1 Increasing geriatric population to aid growth 116
TABLE 71 ITALY: IMAGE-GUIDED RADIATION THERAPY MARKET, BY TECHNIQUE, 2020–2028 (USD MILLION) 116
10.3.6 SPAIN 117
10.3.6.1 Technological developments in healthcare sector to propel market 117
TABLE 72 SPAIN: IMAGE-GUIDED RADIATION THERAPY MARKET, BY TECHNIQUE, 2020–2028 (USD MILLION) 117
10.3.7 REST OF EUROPE 117
TABLE 73 REST OF EUROPE: IMAGE-GUIDED RADIATION THERAPY MARKET, BY TECHNIQUE, 2020–2028 (USD MILLION) 118
10.4 ASIA PACIFIC 118
10.4.1 ASIA PACIFIC: RECESSION IMPACT 118
FIGURE 27 ASIA PACIFIC: MARKET SNAPSHOT 119
TABLE 74 ASIA PACIFIC: IMAGE-GUIDED RADIATION THERAPY MARKET, BY COUNTRY, 2020–2028 (USD MILLION) 120
TABLE 75 ASIA PACIFIC: IMAGE-GUIDED RADIATION THERAPY MARKET, BY TECHNIQUE, 2020–2028 (USD MILLION) 120
TABLE 76 ASIA PACIFIC: IMAGE-GUIDED RADIATION THERAPY MARKET, BY PROCEDURE, 2020–2028 (USD MILLION) 121
TABLE 77 ASIA PACIFIC: IMAGE-GUIDED RADIATION THERAPY MARKET, BY APPLICATION, 2020–2028 (USD MILLION) 121
TABLE 78 ASIA PACIFIC: IMAGE-GUIDED RADIATION THERAPY MARKET, BY END USER, 2020–2028 (USD MILLION) 122
10.4.2 JAPAN 122
10.4.2.1 Japan to hold largest share of APAC market 122
TABLE 79 JAPAN: IMAGE-GUIDED RADIATION THERAPY MARKET, BY TECHNIQUE, 2020–2028 (USD MILLION) 123
10.4.3 CHINA 123
10.4.3.1 Growing prevalence of cancer and developing healthcare infrastructure to aid growth 123
TABLE 80 CHINA: IMAGE-GUIDED RADIATION THERAPY MARKET, BY TECHNIQUE, 2020–2028 (USD MILLION) 124
10.4.4 INDIA 124
10.4.4.1 Increasing target patient population and rising availability of advanced surgical treatments to drive market 124
TABLE 81 INDIA: IMAGE-GUIDED RADIATION THERAPY MARKET, BY TECHNIQUE, 2020–2028 (USD MILLION) 125
10.4.5 AUSTRALIA 125
10.4.5.1 Developing healthcare sector and increasing availability of advanced surgical treatments to favor market 125
TABLE 82 AUSTRALIA: IMAGE-GUIDED RADIATION THERAPY MARKET, BY TECHNIQUE, 2020–2028 (USD MILLION) 125
10.4.6 SOUTH KOREA 126
10.4.6.1 Growing target patient population to drive market 126
TABLE 83 SOUTH KOREA: IMAGE-GUIDED RADIATION THERAPY MARKET, BY TECHNIQUE, 2020–2028 (USD MILLION) 126
10.4.7 REST OF ASIA PACIFIC 127
TABLE 84 REST OF ASIA PACIFIC: IMAGE-GUIDED RADIATION THERAPY MARKET, BY TECHNIQUE, 2020–2028 (USD MILLION) 127
10.5 LATIN AMERICA 127
10.5.1 LATIN AMERICA: RECESSION IMPACT 127
TABLE 85 LATIN AMERICA: IMAGE-GUIDED RADIATION THERAPY MARKET, BY COUNTRY, 2020–2028 (USD MILLION) 128
TABLE 86 LATIN AMERICA: IMAGE-GUIDED RADIATION THERAPY MARKET, BY TECHNIQUE, 2020–2028 (USD MILLION) 128
TABLE 87 LATIN AMERICA: IMAGE-GUIDED RADIATION THERAPY MARKET, BY PROCEDURE, 2020–2028 (USD MILLION) 129
TABLE 88 LATIN AMERICA: IMAGE-GUIDED RADIATION THERAPY MARKET, BY APPLICATION, 2020–2028 (USD MILLION) 129
TABLE 89 LATIN AMERICA: IMAGE-GUIDED RADIATION THERAPY MARKET, BY END USER, 2020–2028 (USD MILLION) 130
10.5.2 BRAZIL 130
10.5.2.1 Developing healthcare sector and increasing availability of advanced surgical treatments to boost market growth 130
TABLE 90 BRAZIL: IMAGE-GUIDED RADIATION THERAPY MARKET, BY TECHNIQUE, 2020–2028 (USD MILLION) 130
10.5.3 MEXICO 131
10.5.3.1 Favorable government initiatives to drive market 131
TABLE 91 MEXICO: IMAGE-GUIDED RADIATION THERAPY MARKET, BY TECHNIQUE, 2020–2028 (USD MILLION) 131
10.5.4 REST OF LATIN AMERICA 132
TABLE 92 REST OF LATIN AMERICA: IMAGE-GUIDED RADIATION THERAPY MARKET, BY TECHNIQUE, 2020–2028 (USD MILLION) 132
10.6 MIDDLE EAST & AFRICA 132
10.6.1 INCREASING FOCUS OF MARKET PLAYERS ON MIDDLE EASTERN COUNTRIES TO PROPEL MARKET 132
10.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 133
TABLE 93 MIDDLE EAST & AFRICA: IMAGE-GUIDED RADIATION THERAPY MARKET, BY TECHNIQUE, 2020–2028 (USD MILLION) 133
TABLE 94 MIDDLE EAST & AFRICA: IMAGE-GUIDED RADIATION THERAPY MARKET, BY PROCEDURE, 2020–2028 (USD MILLION) 133
TABLE 95 MIDDLE EAST & AFRICA: IMAGE-GUIDED RADIATION THERAPY MARKET, BY APPLICATION, 2020–2028 (USD MILLION) 134
TABLE 96 MIDDLE EAST & AFRICA: IMAGE-GUIDED RADIATION THERAPY MARKET, BY END USER, 2020–2028 (USD MILLION) 134
11 COMPETITIVE LANDSCAPE 135
11.1 OVERVIEW 135
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 135
TABLE 97 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN IMAGE-GUIDED RADIATION THERAPY MARKET 136
11.3 REVENUE SHARE ANALYSIS 137
FIGURE 28 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN IMAGE-GUIDED RADIATION THERAPY MARKET, 2018–2022 (USD BILLION) 137
11.4 MARKET RANKING ANALYSIS 138
FIGURE 29 IMAGE-GUIDED RADIATION THERAPY MARKET (2022) 138
11.5 COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2022) 139
11.5.1 STARS 139
11.5.2 EMERGING LEADERS 140
11.5.3 PERVASIVE PLAYERS 140
11.5.4 PARTICIPANTS 140
FIGURE 30 IMAGE-GUIDED RADIATION THERAPY MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022 140
11.6 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022) 141
11.6.1 PROGRESSIVE COMPANIES 141
11.6.2 STARTING BLOCKS 141
11.6.3 RESPONSIVE COMPANIES 141
11.6.4 DYNAMIC COMPANIES 141
FIGURE 31 IMAGE-GUIDED RADIATION THERAPY MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/ SMES, 2022 142
11.7 COMPANY FOOTPRINT ANALYSIS 143
TABLE 98 TECHNIQUE AND REGIONAL FOOTPRINT ANALYSIS OF TOP PLAYERS IN IMAGE-GUIDED RADIATION THERAPY MARKET 143
TABLE 99 FOOTPRINT ANALYSIS OF COMPANIES, BY TECHNIQUE 144
TABLE 100 FOOTPRINT ANALYSIS OF COMPANIES, BY REGION 145
11.8 COMPETITIVE SCENARIOS AND TRENDS 146
TABLE 101 KEY PRODUCT LAUNCHES AND APPROVALS 146
TABLE 102 KEY DEALS 147
TABLE 103 OTHER KEY DEVELOPMENTS 147
12 COMPANY PROFILES 148
(Business overview, Products/Services/Solutions offered, Recent Developments, MNM view)*
12.1 KEY PLAYERS 148
12.1.1 SIEMENS HEALTHINEERS AG 148
TABLE 104 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 148
FIGURE 32 SIEMENS AG: COMPANY SNAPSHOT (2022) 149
12.1.2 HITACHI 153
TABLE 105 HITACHI: COMPANY OVERVIEW 153
FIGURE 33 HITACHI: COMPANY SNAPSHOT (2022) 154
12.1.3 KONINKLIJKE PHILIPS 156
TABLE 106 KONINKLIJKE PHILIPS: COMPANY OVERVIEW 156
FIGURE 34 KONINKLIJKE PHILIPS: COMPANY SNAPSHOT (2022) 157
12.1.4 ELEKTA 160
TABLE 107 ELEKTA: COMPANY OVERVIEW 160
FIGURE 35 ELEKTA: COMPANY SNAPSHOT (2022) 161
12.1.5 ACCURAY INCORPORATED 164
TABLE 108 ACCURAY INCORPORATED: COMPANY OVERVIEW 164
FIGURE 36 ACCURAY INCORPORATED: COMPANY SNAPSHOT (2022) 165
12.1.6 CANON MEDICAL SYSTEMS CORPORATION 168
TABLE 109 CANON MEDICAL SYSTEMS CORPORATION: COMPANY OVERVIEW 168
FIGURE 37 CANON, INC.: COMPANY SNAPSHOT (2022) 169
12.1.7 C-RAD AB 171
TABLE 110 C-RAD: COMPANY OVERVIEW 171
FIGURE 38 C-RAD: COMPANY SNAPSHOT (2022) 172
12.1.8 VIEWRAY, INC. 174
TABLE 111 VIEWRAY, INC.: COMPANY OVERVIEW 174
FIGURE 39 VIEWRAY, INC.: COMPANY SNAPSHOT (2022) 175
12.1.9 IBA WORLDWIDE 177
TABLE 112 IBA: COMPANY OVERVIEW 177
FIGURE 40 IBA: COMPANY SNAPSHOT (2022) 178
12.1.10 VISION RT LTD. 180
TABLE 113 VISION RT LTD.: COMPANY OVERVIEW 180
12.1.11 PANACEA MEDICAL TECHNOLOGIES 182
TABLE 114 PANACEA MEDICAL TECHNOLOGIES: COMPANY OVERVIEW 182
12.1.12 MEVION MEDICAL SYSTEMS 184
TABLE 115 MEVION MEDICAL SYSTEMS: COMPANY OVERVIEW 184
12.1.13 GE HEALTHCARE 186
TABLE 116 GE HEALTHCARE: COMPANY OVERVIEW 186
FIGURE 41 GE HEALTHCARE: COMPANY SNAPSHOT (2022) 187
12.2 OTHER PLAYERS 190
12.2.1 REFLEXION 190
12.2.2 ASG SUPERCONDUCTORS 190
12.2.3 GALBINO TECHNOLOGY 191
12.2.4 IZI MEDICAL 191
12.2.5 XSTRAHL 192
12.2.6 AEP LINAC 192
*Details on Business overview, Products/Services/Solutions offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
 
13 APPENDIX 193
13.1 DISCUSSION GUIDE 193
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 199
13.3 CUSTOMIZATION OPTIONS 201
13.4 RELATED REPORTS 201
13.5 AUTHOR DETAILS 202